Antidiabetic drug voglibose is protective against ischemia-reperfusion injury through glucagon-like peptide 1 receptors and the phosphoinositide 3-kinase-akt-endothelial nitric oxide synthase pathway in rabbits

Journal of Cardiovascular Pharmacology

Volumn 55, Issue 6, 2010, Pages 625-634

  Iwasa, Masamitsu ^a   Kobayashi, Hiroyuki ^a   Yasuda, Shinji ^a   Kawamura, Itta ^a   Sumi, Shohei ^a   Yamada, Yoshihisa ^a   Shiraki, Takeru ^a   Yamaki, Takahiko ^a   Ushikoshi, Hiroaki ^a   Aoyama, Takuma ^a   Nishigaki, Kazuhiko ^a   Takemura, Genzou ^a   Fujiwara, Takako ^b   Fujiwara, Hisayoshi ^c   Minatoguchi, Shinya ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO WOMEN'S UNIVERSITY   (Japan)

^c HYOGO PREFECTURAL AMAGASAKI GENERAL MEDICAL CENTER   (Japan)

Author keywords

Akt; eNOS; GLP 1; ischemia reperfusion; KATP channel; voglibose

Indexed keywords

5 HYDROXYDECANOIC ACID; ANTIDIABETIC AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EXENDIN 4; EXENDIN[9-39]; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; N(G) NITROARGININE METHYL ESTER; PHOSPHATIDYLINOSITOL 3 KINASE; POTASSIUM CHANNEL; PROTEIN KINASE B; UNCLASSIFIED DRUG; VOGLIBOSE; WORTMANNIN; 5-HYDROXYDECANOIC ACID; ALPHA GLUCOSIDASE; ARGININE; DECANOIC ACID DERIVATIVE; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HYDROXYACID; INOSITOL; NITRIC OXIDE SYNTHASE; NOS3 PROTEIN, HUMAN; PHOSPHOTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; NONHUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; RABBIT; REPERFUSION INJURY; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; HEART; HEART MUSCLE; MALE; METABOLISM; PATHOPHYSIOLOGY;

ALPHA-GLUCOSIDASES; ANIMALS; ARGININE; DECANOIC ACIDS; GLUCAGON-LIKE PEPTIDE 1; HEART; HYDROXY ACIDS; HYPOGLYCEMIC AGENTS; INOSITOL; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIUM; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHOTRANSFERASES; PROTO-ONCOGENE PROTEINS C-AKT; RABBITS; RECEPTORS, GLUCAGON; REPERFUSION INJURY;

EID: 77953807602     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181dcd240     Document Type: Article

References (22)

1. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-444.
2. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS34). Lancet. 1998;352:854-865.
3. Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999;22:920-924
4. Bischoff H. Pharmacology of a-glucosidase inhibition. European Journal of Clinical Investigation. 1994;24(Suppl 3):3-10.
5. Satoh N, Shimatsu A, Yamada K, et al. An alpha-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients. Metabolism. 2000; 55:786-793.
6. Goke B, Fuder H, Wieckhorst G, et al. Voglivose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion. 1995;56:493-501.
7. Moritoh Y, Takeuchi K, Hazama M. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice. J Pharmacol Exp Ther. 2009;329:669-676.
8. Bose AK, Mocanu MM, Carr RD, et al. Glucagon-like peptide-1 can directly protect the heart against ischemia/reperfusion injury. Diabetes. 2005;50:146-151.
9. Ban K, Noyan-Ashraf MH, Hoefer J, et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008;117:2340-2350.
10. Timmers L, Henriques JPS, de Kleijin DPV, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol. 2009;53:501-510.
11. Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486-494.
12. Ebel D, Mullenheim J, Frassdorf J, et al. Effect of acute hyperglycemia and diabetes mellitus with and without short-term insulin treatment on myocardial ischaemic late preconditioning in rabbit heart in vivo. Pflugers Arch. 2003;446:175-182.
13. Franz S, Calvillo L, Tillmanns J, et al. Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury: prevention by the a-glucosidase inhibitor acarbose. FASEB J. 2005;19:591-593.
14. Liu Y, Sato T, O'Rourke B, et al. Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection? Circulation. 1998;97:2463-2469.
15. Kersten JR, Schmeling TJ, Orth KG, et al. Acute hyperglycemia abolishes ischemic preconditioning in vivo. Am J Physiol. 1998;275:H721-H725.
16. Kersten JR, Montgomery MW, Ghassemi T, et al. Diabetes and hyperglycemia impair activation of mitochondrial KATP channels. Am J Physiol Heart Circ Physiol. 2001;280:H1744-H1750.
17. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3: 153-165.
18. Buteau J, Roduit R, Susini S, et al. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia. 1999;42: 856-864.
19. Hausenloy DJ, Tsang A, Mocanu MM, et al. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol. 2005;288:H971-H976.
20. Takano H, Manchikalapudi S, Tang XL, et al. Nitric oxide synthase is the mediator of late preconditioning against myocardial infarction in conscious rabbits. Circulation. 1998;98:441-449.
21. Lebuffe G, Schumacker PT, Shao ZH, et al. ROS and NO trigger early preconditioning: relationship to mitochondrial KATP channel. Am J Physiol Heart Circ Physiol. 2003;284:H299-H308.
22. Zhu M, Feng J, Lucchinetti E, et al. Ischemic postconditioning protects remodeled myocardium via the PI3K-PKB/Akt reperfusion injury salvage kinase pathway. Cardiovasc Res. 2006;72:152-162.